PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise in shrinking melanoma before surgery
Disease control OngoingThis study tests whether adding an experimental drug (CMP-001) to the immunotherapy pembrolizumab can better shrink melanoma tumors before surgery and help prevent the cancer from coming back. About 60 adults with stage III or recurrent melanoma that can be surgically removed wil…
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 16, 2026 23:48 UTC
-
New triple therapy aims to tame immunotherapy side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to two standard immunotherapy drugs (ipilimumab and nivolumab) can reduce severe side effects while still fighting cancer. About 35 adults with advanced melanoma, non-small cell lung cancer, or bladder cancer will receive the combinatio…
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 16, 2026 23:46 UTC
-
New hope for transplant patients with advanced skin cancer: immune drugs may control tumors without losing the kidney
Disease control OngoingThis early-phase study tests whether combining immune-boosting drugs (nivolumab and ipilimumab) with a transplant-protecting drug (tacrolimus) can shrink or control advanced skin cancers in kidney transplant recipients. The goal is to treat the cancer while keeping the donated ki…
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug combo aims to supercharge immune attack on melanoma
Disease control OngoingThis early-phase study tests whether adding an experimental drug (VX15/2503) to standard immunotherapy (ipilimumab or nivolumab) helps the immune system better attack stage III melanoma that can be removed by surgery. About 41 adults with resectable melanoma will receive the drug…
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Melanoma patients may get a break from therapy thanks to PET scans
Disease control OngoingThis study looks at whether doctors can safely stop standard anti-PD-1 immunotherapy early in people with advanced melanoma that cannot be surgically removed. Using PET/CT scans and tumor biopsies as guides, the goal is to see if stopping treatment sooner still keeps the cancer u…
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Immune cell army plus drug shows promise against tough melanoma
Disease control OngoingThis early-stage trial tests a two-pronged attack on advanced melanoma. First, doctors remove some of the patient's own immune cells from a tumor, grow them into a larger army in a lab (Lifileucel), and put them back. Second, they give the drug pembrolizumab to help those cells w…
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Richard Wu • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Melanoma study aims to uncover hidden toll of immunotherapy
Knowledge-focused OngoingThis study looks at side effects and quality of life in people with melanoma who are getting immunotherapy after surgery. Researchers will track symptoms, blood markers, and how patients feel over two years. The goal is to learn more about why some people have side effects and ho…
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 16, 2026 23:49 UTC
-
Facebook group aims to boost skin checks in young melanoma families
Knowledge-focused OngoingThis study tests whether a private Facebook group can help young adults (ages 18-39) diagnosed with early-stage melanoma and their close relatives do more skin checks and use better sun protection. About 1,160 participants from New Jersey, California, and Texas will join either a…
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated May 07, 2026 18:38 UTC